469 related articles for article (PubMed ID: 15200450)
41. The Trio Trial - A Randomized Controlled Clinical Trial Evaluating the Effect of a Biocompatible Peritoneal Dialysis Solution on Residual Renal Function.
Sikaneta T; Wu G; Abdolell M; Ng A; Mahdavi S; Svendrovski A; Tu T; Mercer T; Tong M; Oreopoulos D; Tam P
Perit Dial Int; 2016 9-10; 36(5):526-32. PubMed ID: 27282852
[TBL] [Abstract][Full Text] [Related]
42. Could solutions low in glucose degradation products preserve residual renal function in incident peritoneal dialysis patients? A 1-year multicenter prospective randomized controlled trial (Balnet Study).
Kim SG; Kim S; Hwang YH; Kim K; Oh JE; Chung W; Oh KH; Kim HJ; Ahn C;
Perit Dial Int; 2008 Jun; 28 Suppl 3():S117-22. PubMed ID: 18552239
[TBL] [Abstract][Full Text] [Related]
43. Impact of combination therapy with peritoneal dialysis and hemodialysis on peritoneal function.
Moriishi M; Kawanishi H; Tsuchiya S
Adv Perit Dial; 2010; 26():67-70. PubMed ID: 21348383
[TBL] [Abstract][Full Text] [Related]
44. The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis.
Do JY; Kim YL; Park JW; Chang KA; Lee SH; Ryu DH; Kim CD; Park SH; Yoon KW
Perit Dial Int; 2008 Jun; 28 Suppl 3():S101-6. PubMed ID: 18552237
[TBL] [Abstract][Full Text] [Related]
45. Peritoneal equilibration test with conventional 'low pH/high glucose degradation product' or with biocompatible 'normal pH/low glucose degradation product' dialysates: does it matter?
Van Overmeire L; Goffin E; Krzesinski JM; Saint-Remy A; Bovy P; Cornet G; Bovy C
Nephrol Dial Transplant; 2013 Jul; 28(7):1946-51. PubMed ID: 23223220
[TBL] [Abstract][Full Text] [Related]
46. Vascular endothelial growth factor (VEGF) levels in peritoneal dialysis effluent.
Selgas R; del Peso G; Bajo MA; Molina S; Cirugeda A; Sánchez-Tomero JA; Castro MJ; Castro MA; Vara F
J Nephrol; 2001; 14(4):270-4. PubMed ID: 11506249
[TBL] [Abstract][Full Text] [Related]
47. Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells.
Witowski J; Korybalska K; Ksiazek K; Wisniewska-Elnur J; Jörres A; Lage C; Schaub TP; Passlick-Deetjen J; Breborowicz A; Grzegorzewska A; Ksiazek A; Liberek T; Lichodziejewska-Niemierko M; Majdan M; Rutkowski B; Stompór T; Sulowicz W
Nephrol Dial Transplant; 2004 Apr; 19(4):917-24. PubMed ID: 15031350
[TBL] [Abstract][Full Text] [Related]
48. Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model.
Mortier S; Faict D; Lameire NH; De Vriese AS
Kidney Int; 2005 Apr; 67(4):1559-65. PubMed ID: 15780112
[TBL] [Abstract][Full Text] [Related]
49. Short-term effects of bicarbonate/lactate-buffered and conventional lactate-buffered dialysis solutions on peritoneal ultrafiltration: a comparative crossover study.
Pajek J; Kveder R; Bren A; Gucek A; Bucar M; Skoberne A; Waniewski J; Lindholm B
Nephrol Dial Transplant; 2009 May; 24(5):1617-25. PubMed ID: 19066345
[TBL] [Abstract][Full Text] [Related]
50. Effects of low-glucose degradation product solution on peritoneal membrane characteristics in peritoneal dialysis patients: a 3-year follow-up study.
Park JW; Kang SH; Do JY
Iran J Kidney Dis; 2014 Jan; 8(1):58-64. PubMed ID: 24413723
[TBL] [Abstract][Full Text] [Related]
51. The Effect of Neutral Peritoneal Dialysis Solution with Low Glucose-Degradation-Product on the Fluid Status and Body Composition--A Randomized Control Trial.
Szeto CC; Kwan BC; Chow KM; Cheng PM; Kwong VW; Choy AS; Law MC; Leung CB; Li PK
PLoS One; 2015; 10(10):e0141425. PubMed ID: 26510186
[TBL] [Abstract][Full Text] [Related]
52. Does the biocompatibility of the peritoneal dialysis solution matter in assessment of peritoneal function?
Parikova A; Struijk DG; Zweers MM; Langedijk M; Schouten N; van den Berg N; Duis S; Krediet RT
Perit Dial Int; 2007; 27(6):691-6. PubMed ID: 17984433
[TBL] [Abstract][Full Text] [Related]
53. Influence of pH-neutral peritoneal dialysis solution.
Moriishi M; Kawanishi H; Kawai T; Takahashi S; Hirai T; Shishida M; Watanabe H; Takahashi N
Adv Perit Dial; 2002; 18():68-71. PubMed ID: 12402590
[TBL] [Abstract][Full Text] [Related]
54. Low concentrations of glucose degradation products in peritoneal dialysis fluids and their impact on biocompatibility parameters: prospective cross-over study with a three-compartment bag.
Cappelli G; Bandiani G; Cancarini GC; Feriani M; Dell'Aquila R; Saffioti S; Spisni C; Stingone A; Orazi E; Ballocchi S; Renaux JL
Adv Perit Dial; 1999; 15():238-42. PubMed ID: 10682110
[TBL] [Abstract][Full Text] [Related]
55. Impact of a low-glucose peritoneal dialysis regimen on fibrosis and inflammation biomarkers.
Yung S; Lui SL; Ng CK; Yim A; Ma MK; Lo KY; Chow CC; Chu KH; Chak WL; Lam MF; Yung CY; Yip TP; Wong S; Tang CS; Ng FS; Chan TM
Perit Dial Int; 2015; 35(2):147-58. PubMed ID: 25904773
[TBL] [Abstract][Full Text] [Related]
56. In vivo exposure to bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improves ex vivo peritoneal macrophage function.
Mackenzie RK; Jones S; Moseley A; Holmes CJ; Argyle R; Williams JD; Coles GA; Pu K; Faict D; Topley N
Am J Kidney Dis; 2000 Jan; 35(1):112-21. PubMed ID: 10620552
[TBL] [Abstract][Full Text] [Related]
57. Differences in peritoneal response after exposure to low-GDP bicarbonate/lactate-buffered dialysis solution compared to conventional dialysis solution in a uremic mouse model.
Vila Cuenca M; Keuning ED; Talhout W; Paauw NJ; van Ittersum FJ; Ter Wee PM; Beelen RHJ; Vervloet MG; Ferrantelli E
Int Urol Nephrol; 2018 Jun; 50(6):1151-1161. PubMed ID: 29728994
[TBL] [Abstract][Full Text] [Related]
58. Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function.
Johnson DW; Clarke M; Wilson V; Woods F; Brown FG
BMC Nephrol; 2010 Sep; 11():25. PubMed ID: 20843375
[TBL] [Abstract][Full Text] [Related]
59. Short-term effects of a new bicarbonate/lactate-buffered and conventional peritoneal dialysis fluid on peritoneal and systemic inflammation in CAPD patients: a randomized controlled study.
Pajek J; Kveder R; Bren A; Gucek A; Ihan A; Osredkar J; Lindholm B
Perit Dial Int; 2008; 28(1):44-52. PubMed ID: 18178947
[TBL] [Abstract][Full Text] [Related]
60. Biocompatible peritoneal dialysis solutions: do they indeed affect the outcome?
Grzegorzewska AE
Pol Arch Med Wewn; 2009 Apr; 119(4):242-7. PubMed ID: 19413184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
